Effectiveness of intranasal vaccination against Angiostrongylus costaricensis using a serine/threonine phosphatase 2 A synthetic peptide and recombinant antigens.
Intranasal immunization was assayed in C57BL/6 mice against Angiostrongylus costaricensis using a synthetic and a recombinant peptide belonging to the catalytic region of the serine/threonine phosphatase 2 A (PP2A) of the parasite. Immunization was carried out with the synthetic peptide (SP) polymerized either with itself or with the beta fraction of the cholera toxin (CTB) and then enclosed in nanocapsules of phosphatidyl choline, cholesterol and Quil A (ISCOM). Another group of mice was immunized with recombinant peptide. Immunization consisted of two intranasal inoculations at two-week intervals, and the challenge with L3 larvae was made one month after the last vaccination. The effectiveness of immunization was evaluated 30 days after infection by analysis of the number of parasites in the arteries of the immunized mice, as well as by measuring spleen sizes in the experimental groups. The response induced was determined by identifying the isotypes of IgG as well as the IgE and IgA specific antigen response. The interleukins produced by the splenocyte culture of the different groups were assessed after exposing them to the peptide used in the immunization. From our results, 60%, 80%, and 100% protection against the A. costaricensis challenge was achieved in mice immunized with polymerized synthetic peptide in ISCOM, synthetic peptide polymerized with the CTB in ISCOM and inclusion bodies respectively. Splenomegaly was found to be less evident in the immunized mice than in the controls. A significant increase in IFN gamma and IL-17 levels was observed in the group with 100% protection. The results showed that vaccination through the nasal mucosa may constitute a useful method of immunization and result in a protective immune response against A. costaricensis.
Solano-Parada
J
J
Institute of Biotechnology, Biochemistry and Molecular Parasitology Group, University of Granada, Edif Mecenas, Campus Fuentenueva, 18071 Granada, Spain.
Gonzalez-Gonzalez
G
G
Torró
L M de Pablos
LM
dos Santos
M F Brazil
MF
Espino
A M
AM
Burgos
M
M
Osuna
A
A
D000281:Administration, Intranasal; D000595:Amino Acid Sequence; D000801:Angiostrongylus / Q000201:enzymology / Q000276:immunology; D000818:Animals; D000909:Antibodies, Helminth / Q000097:blood; D000947:Antigens, Helminth / Q000276:immunology*; D001483:Base Sequence; D002772:Cholera Toxin / Q000276:immunology; D005260:Female; D016882:ISCOMs / Q000276:immunology; D007378:Interleukins / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D053769:Nanocapsules; D009297:Nasal Mucosa / Q000276:immunology; D009929:Organ Size; D054648:Protein Phosphatase 2 / Q000276:immunology*; D013154:Spleen / Q000166:cytology / Q000276:immunology; D017206:Strongylida Infections / Q000276:immunology / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000276:immunology*
D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D016882:ISCOMs; D007378:Interleukins; D053769:Nanocapsules; D014614:Vaccines, Synthetic; D002772:Cholera Toxin; D054648:Protein Phosphatase 2